In late July, the U.S. Food and Drug Administration warned consumers that several pharmaceutical companies have initiated recalls of the popular blood pressure drug valsartan after discovering that the medication is contaminated with a potentially carcinogenic chemical.
Recently, the FDA posted a voluntary recall from Raritan Pharmaceuticals of homeopathic children's remedies containing belladonna extract. Belladonna, also known as "deadly nightshade," is a plant traditionally used in herbal remedies that can be poisonous, and even fatal, if consumed in a sufficiently large dose. The recall affects the following Raritan products: Kids Relief Homeopathic Ear Relief Oral Liquid, CVS Homeopathic Kids' Ear Relief Liquid, and CVS Homeopathic Infants' Teething Tablet.
Dozens of lots of the generic version of the cholesterol drug Lipitor have been recalled because they may contain tiny glass particles. Ranbaxy Pharmaceuticals, a subsidiary of Ranbaxy Laboratories Ltd. is operating under increased scrutiny from the United States Food and Drug Administration (FDA) because of possible multiple quality lapses at several of its factories over the past several years.
GlaxoSmithKline has decided to recall 394,230 bottles of its DynaCirc CR from the United States market. DynaCirc CR, a drug used to treat hypertension, is being pulled from the market due to inconsistent packaging practices. Novartis, the drug's manufacturer, has had issues with the integrity of it packaging out of its Lincoln, Nebraska plant. The packaging problems were identified by the United States Food and Drug Administration (FDA). Among the chief concerns cited by FDA inspectors were reports of tablets of certain medicines being placed in bottles labeled for other products. GlaxoSmithKline, a London-based company, said it issued the voluntary recall of all bottles of DynaCirc CR remaining in the United States market from wholesalers, pharmacies, and hospitals. Reports of adverse events do not exist at this point but Glaxo moved forward with the recall as a precautionary measure. As a result of the recall, the drug will not be available to patients, however there are alternative treatments available to patients currently being treated with DynaCirc.